Mallia strengthens its advisory board as it accelerates hair loss treatment
Ella Day | July 7, 2025 | Appointment | Manufacturing and Production | Dermatology, Skin, biopharma, dermatology, hair loss, mallia
German dermatology company, Mallia Innovations, has appointed Jens Holstein, Alexandra Ogilvie and Ulrich Dauer to its advisory board, strengthening its leadership as it develops its CD83 protein for hormonal hair loss.
Jens Holstein brings over 25 years of leadership experience in the biopharma sector. For the past four years, he was chief scientific officer (CFO) at BioNTech, and prior to that, he served nearly a decade as CFO of MorphoSys.
Alexandra Ogilvie is a dermatologist with over three decades of clinical experience. She is the founder of Skin Concept, a renowned dermatology clinic in Munich, Germany, and is active on numerous German and international scientific advisory boards.
Ulrich Dauer is a former CEO of several biopharma companies, including Vivoryon Therapeutics, OMEICOS Therapeutics and 4SC, which he founded. He is experienced in strategic leadership, clinical development and corporate financing.
Co-founder and managing director of Mallia, Manfred Gröppel, commented on the appointments: “Their track records in advancing innovative therapeutics, building successful life sciences companies and providing practical clinical insights will be instrumental in the further development of our CD83-based therapies for hair loss and cosmetic hair stimulation products.”
CD83 is currently in development for the topical treatment of hair loss and stimulation of hair growth, forming part of Mallia’s focus on hair growth, hair loss and other dermatological indications.
This article featured in: July 2025 – The Pharmafile Brief
Related Content
Chronic spontaneous urticaria – the impact on patient quality of life, ongoing developments in treatments and the importance of greater awareness
The current forms of immunotherapy, how T cell therapy works and what the future holds
Symeres announces acquisition of DGr Pharma
Symeres, a Contract Research, Development and Manufacturing Organization (CRDMO) has acquired DGr Pharma, a drug …
Galderma launches clinical trials for nemolizumab in systemic sclerosis and chronic pruritus of unknown origin
Galderma has announced the launch of two phase 2 clinical trials evaluating its monoclonal antibody, …
